DAM
PLX icon

Deltec Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Deltec Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-19,245
Closed -$466K – 153
2014
Q3 		$466K Sell
19,245
-10
-0.1% -$288 0.1% 100
2014
Q2 		$703K Buy
19,255
+8,308
+76% +$335K 0.15% 90
2014
Q1 		$501K Buy
+10,947
New +$511K 0.11% 97

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Deltec Asset Management's PLX Position: Q4 2014 in Review

Deltec Asset Management sold out of Protalix BioTherapeutics (PLX) in Q4 2014, closing a stake of 19,245 shares — an estimated $466K sold.

Deltec Asset Management first reported a position in PLX in Q1 2014 and held it in 3 quarters. The position peaked at $703K in Q2 2014. 44 funds tracked by Wall St. Rank hold PLX as of Q4 2014.

  • Deltec Asset Management reported no remaining Protalix BioTherapeutics position as of Q4 2014 after selling out during the quarter.
  • Deltec Asset Management sold 19,245 Protalix BioTherapeutics shares in Q4 2014, an estimated $466K.
  • Deltec Asset Management first reported a position in Protalix BioTherapeutics in Q1 2014 and held it in 3 quarters.
  • Deltec Asset Management's Protalix BioTherapeutics position peaked at $703K in Q2 2014.
  • 44 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2014.

Based on Deltec Asset Management's 13F filing for Q4 2014, filed 3 Feb 2015.